ASPARTATE AMINOTRANSFERASE INCREASED and RIBASPHEREPatientsVille
ASPARTATE AMINOTRANSFERASE INCREASED Symptoms and Causes
We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.
Check out the latest treatments for ASPARTATE AMINOTRANSFERASE INCREASED
Find Drug Side Effect reports
I have been put on Molipaxin 3 weeks ago, I have dry mouth, hair loss and my panic attacks were showing no signs of improvement. Dr increased it to 100mg and put me onto Lamictin. I am not bi polar nor epileptic. My disorder ist algora phoebia. I a
Have taken hydrea for a year because my spleen had increased in size. I have noticed increased loss of memory and some confusion for the past couple of months. I take 500 mg every other day and 1000 mg every other day.
Unresponsive to 5mg/kg q 8wks; increased to 10mg/kg q6wks. After 3 doses at that strength noted fatigue, occasional night sweats, joint aches, sudden onset of chest pain and dyspnea (pleurisy, small pleuraleffusion) Had just taper
<strong>I took 2 capsules at 7.20m after having breakfast and started feeling side effects at 8.25am. It started with increased temperature, abnormal levels of perspiration, dizziness and severe nausea. </strong
1+ years on this carvedilol 12.5 once a day then increased to 2x per day. Asthma symptoms, tightness in the chest, confusion, dizziness, some heart palpitation, ringing in the ears, disorientation (the worst). 57 yr old male, reasonable health for a
10 years on effexor, weight gain of 20 lbs last 5 years when increased to 300mg., no change in cal or exercise, since getting older realized needed fewre calories so tried to reduce like always could wirhWW and exercise, no success, couldn'
ASPARTATE AMINOTRANSFERASE INCREASED Clinical Trials and StudiesTreatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients
Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)
In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia
RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)
Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection
|10||Not yet recruiting||
A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)
Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection
Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment
Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients
Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?
An Open Label Trial of Pegylated Interferon, Ribavirin and Telaprevir Versus Pegylated Interferon and Ribavirin Alone in the Treatment of Hepatitis C Genotype 1 Virus Infection in Patients With HIV-1 Co-infection
Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies
Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients